Zalsupindole,[1] also known by its developmental code names DLX-001 and AAZ-A-154 and as (R)-5-methoxy-N,N-dimethyl-α-methylisotryptamine, is a novel isotryptamine derivative which acts as a serotonin 5-HT2A receptor agonist discovered and synthesized by the lab of Professor David E. Olson at the University of California, Davis.

[2][3] Animal studies suggest that it produces antidepressant effects without the psychedelic action typical of drugs from this class.

[8][4][5] Due to the rapidly-induced and enduring neuroplasticity, zalsupindole is a member of the class of compounds known as non-hallucinogenic psychoplastogens.

[9][4][5] A phase 1 dose-ranging clinical trial confirmed that zalsupindole is non-hallucinogenic in humans across a dose range of 2 to 360 mg.[10] The drug is selective for the serotonin 5-HT2 receptors.

[13] Zalsupindole, as well as related compounds, are licensed by Delix Therapeutics and are being developed as potential medicines for neuropsychiatric disorders.